Why is Teladoc stock falling?

Teladoc stock fell in after-hours trading Tuesday after the telehealth giant posted fourth-quarter earnings, despite results exceeding Wall Street's expectations on profit and revenue.

Is Teladoc Health stock a good buy?

Teladoc Health, Inc. (NYSE:TDOC) delivered a -39.02% return since the beginning of the year, while its 12-month returns are down by -67.23%. The stock closed at $55.99 per share on April 25, 2022. "Teladoc is the largest telehealth provider in the US and has recently begun to expand internationally.

Will Teladoc ever recover?

Despite the stock's steady decline over the past year, Teladoc Health still holds a promising future due to its disruptive model. According to Tulane University School of Public Health and Tropical Medicine, Telemedicine is here to stay for the foreseeable future.

Is Teladoc overvalued?

Valuation metrics show that Teladoc Health, Inc. may be overvalued. Its Value Score of D indicates it would be a bad pick for value investors. The financial health and growth prospects of TDOC, demonstrate its potential to underperform the market.

Is Teladoc going under?

Shares of struggling telehealth company Teladoc Health (TDOC 4.03%) collapsed after it recently released earnings for the first quarter of 2022. After shooting to roughly $300 per share in early 2021, the stock sits at just under $40, a staggering decline of more than 80%.

Teladoc stock: 40% DROP! TDOC stock analysis

Will Teladoc ever be profitable?

The telehealth giant isn't yet profitable and reported a loss of $84.3 million in the third quarter of 2021, deeper than its year-prior loss of $36 million. Shares of Teladoc stock fell 6.2% on Monday as of 10:47 a.m. in New York.

Is TDOC a Buy Sell or Hold?

Out of 27 analysts, 6 (22.22%) are recommending TDOC as a Strong Buy, 5 (18.52%) are recommending TDOC as a Buy, 16 (59.26%) are recommending TDOC as a Hold, 0 (0%) are recommending TDOC as a Sell, and 0 (0%) are recommending TDOC as a Strong Sell. What is TDOC's earnings growth forecast for 2022-2024?

Is TDOC undervalued?

TDOC outperformed the market since our April update, increasing its near-term support's resilience. However, we have not observed a bear trap to help reverse its bearish bias. Our reverse cash flow valuation model indicates a more reasonable valuation for Teladoc. However, it's still not undervalued.

Is teladoc a good company?

The employee experience below at Teladoc Health (formerly Livongo), compared to a typical company. 84% of employees at Teladoc Health (formerly Livongo) say it is a great place to work compared to 57% of employees at a typical U.S.-based company. Source: Great Place to Work® 2021 Global Employee Engagement Study.

Who are teladoc competitors?

Teladoc Health's top competitors include naviHealth, Lash Group, Amwell, 98point6, MDLIVE, Providence Service Corporation and Sharecare. Teladoc Health is a telehealth company that uses telephone and video conferencing technology to provide on-demand remote medical care via mobile devices, the internet, and video.

What was teladoc IPO price?

Telehealth platform company Teladoc, on Tuesday, announced that its initial public offering would be priced at $19 per share, raising $157 million, according to a Renaissance Capital post to NASDAQ.com.

What is the future of Teladoc stock?

First, the company expects its net loss to continue shrinking. For fiscal 2022, Teladoc projected it would report a net loss per share between $1.60 and $1.40. At this rate, Teladoc could become profitable by 2024.

Is Teladoc an acquisition target?

As a reader, you need to bear in mind that Teladoc is an acquisition vehicle; we thus need to consider that its "struggle towards profitability" has been down to transitory costs rather than a flawed business model.

Is Teladoc a healthcare stock?

This healthcare stock has stellar long-term growth prospects. Teladoc Health (TDOC 6.94%) offers virtual healthcare services in the United States and internationally, with primary and specialty care telehealth solutions along with chronic care and mental healthcare.

What do analysts say about teladoc?

Teladoc Health Inc (NYSE:TDOC)

The 24 analysts offering 12-month price forecasts for Teladoc Health Inc have a median target of 43.50, with a high estimate of 141.00 and a low estimate of 30.00. The median estimate represents a +21.61% increase from the last price of 35.77.

Is Nvidia a sell?

Nvidia has the potential to grow for many years.

Nvidia (NVDA 5.55%) has seen its share price fall nearly 50% since peaking at $346 in late 2021, but the graphics-chip leader has continued to deliver lots of growth for investors.

Is docu a buy?

The sell-side's consensus sales increase estimate for DOCU in Q1 FY 2023 is +24.0% (versus +23.9% for management guidance); and the analysts see DocuSign generating a revenue growth of +17.6% for full-year fiscal 2023 (versus management's expectations of +17.5%).

What is teladoc PE ratio?

Teladoc Health's p/e ratio (fwd) is -24.9x. Teladoc Health's p/e ratio (fwd) is expected to average -71.4x over the next five fiscal years.

Will Etsy go up?

The 18 analysts offering 12-month price forecasts for ETSY Inc have a median target of 127.50, with a high estimate of 268.00 and a low estimate of 75.00. The median estimate represents a +72.04% increase from the last price of 74.11.

Is Teladoc owned by Aetna?

Teladoc and Teladoc physicians are independent contractors and are not agents of Aetna. For a complete description of the limitations of Teladoc services, visit Teladoc.com/Aetna. Teladoc, Teladoc Health and the Teladoc Health logo are registered trademarks or trademarks of Teladoc Health, Inc.